KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $1.5 billion.

  • Biomarin Pharmaceutical's Cash & Current Investments rose 5883.16% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 5883.16%. This contributed to the annual value of $1.1 billion for FY2024, which is 595.04% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Cash & Current Investments stood at $1.5 billion, which was up 5883.16% from $1.4 billion recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Cash & Current Investments high stood at $1.5 billion for Q3 2025, and its period low was $930.4 million during Q3 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's median Cash & Current Investments value was $1.1 billion (recorded in 2023), while the average stood at $1.2 billion.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 2830.61% in 2021, then skyrocketed by 5883.16% in 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Cash & Current Investments (Quarter) stood at $1.0 billion in 2021, then increased by 27.39% to $1.3 billion in 2022, then decreased by 16.86% to $1.1 billion in 2023, then rose by 5.95% to $1.1 billion in 2024, then rose by 29.9% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.3 billion during Q1 2025.